ReviewInternational journal of molecular sciences2020
Determinants of Resistance to Checkpoint Inhibitors.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 44 citations in OpenAlex.
- Epigenetic modifiers to enhance the efficacy of immune checkpoint inhibitors for the treatment of melanoma.Translational oncology · 2025Review
- Radionuclide-Dependent Stimulation of Antitumor Immunity in GD2-Targeted Radiopharmaceutical Therapy Combined with Immune Checkpoint Inhibitors.Radiation (Multidisciplinary Digital Publishing Institute) · 2025Article
- Oleate alters the immune response in non-small cell lung adenocarcinoma through regulation of HMGB1 release.Frontiers in cell and developmental biology · 2024Article
- Unsaturated fatty acid alters the immune response in non-small cell lung adenocarcinoma through regulation of HMGB1 trafficking.bioRxiv : the preprint server for biology · 2023Article
- Bladder cancer.Nature reviews. Disease primers · 2023Review
- Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer.BMC cancer · 2023Article
- Inflammation Control and Immunotherapeutic Strategies in Comprehensive Cancer Treatment.Metabolites · 2023Article
- The relationship between autophagy and PD-L1 and their role in antitumor therapy.Frontiers in immunology · 2023Review
- Review
- Immune checkpoint inhibitors for the treatment of melanoma.Expert opinion on biological therapy · 2022Review
- Acquired resistance for immune checkpoint inhibitors in cancer immunotherapy: challenges and prospects.Aging · 2022Review
- Failure of Immunotherapy-The Molecular and Immunological Origin of Immunotherapy Resistance in Lung Cancer.International journal of molecular sciences · 2021Review
- Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.The oncologist · 2021Article
- Thinking Small: Small Molecules as Potential Synergistic Adjuncts to Checkpoint Inhibition in Melanoma.International journal of molecular sciences · 2021Review
- Advances in bladder cancer biology and therapy.Nature reviews. Cancer · 2021Review
- Review
- Cancer-Associated Fibroblasts and Tumor-Associated Macrophages in Cancer and Cancer Immunotherapy.Frontiers in oncology · 2021Review
- TNF Family-Based Signature Predicts Prognosis, Tumor Microenvironment, and Molecular Subtypes in Bladder Carcinoma.Frontiers in cell and developmental biology · 2021Article
- The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy.Frontiers in oncology · 2021Review
- Mining the Gut Microbiota for Microbial-Based Therapeutic Strategies in Cancer Immunotherapy.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The development of immune checkpoint inhibitors (ICIs) has drastically altered the landscape of cancer treatment. Since approval of the first ICI for the treatment of advanced melanoma in 2011, several therapeutic agents have been Food and Drug Administration (FDA)-approved for multiple cancers, and hundreds of clinical trials are currently ongoing. These antibodies disrupt T-cell inhibitory pathways established by tumor cells and thus re-activate the host's antitumor immune response. While successful in many cancers, several types remain relatively refractory to treatment or patients develop early recurrence. Hence, there is a great need to further elucidate mechanisms of resistant disease and determine novel, effective, and tolerable combination therapies to enhance efficacy of ICIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.